Kazia Therapeutics Limited (KZIA) News and press releases

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is pleased to announce that it has entered into a collaboration with the Australian and New Zealand Children's Haematology / Oncology Group (ANZCHOG) for a phase II clinical study examining paxalisib in children with advanced solid tumours, including brain tumours.

Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.

On Thursday, 116 companies set new 52-week lows.

Melbourne, Victoria--News Direct--Kazia Therapeutics Ltd ((ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner speaks with Proactive after confirming a two-tranche capital raising initiative to raise A$4.5 million through

SYDNEY, Jan. 16, 2023 /PRNewswire/ -- Kazia Therapeutics Limited ((ASX: KZA, NASDAQ:KZIA), an Australian oncology-focused biotechnology company, is pleased to announce a placement of KZA shares, to institutional and

Sydney, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: Dynamic Metals Ltd (ASX:DYM) has